Emyria (ASX: EMD) Delivers Record Revenue as Veterans’ Healthcare and US Opportunities Open a New Growth Chapter

Emyria Limited (ASX: EMD) is beginning to demonstrate the commercial potential of its specialist mental health treatment network, with September-quarter revenue reaching a record $1.42 million as the company expands nationally and secures its first Department of Veterans’ Affairs (DVA) treatment approvals.

The latest quarterly presentation, released on 2 November 2026, reinforces the progress made across its Australian clinic network and highlights emerging international opportunities. With growing treatment capacity, more than 40 veterans in its referral pipeline and increasing recognition in the US, Emyria is positioning itself for an important stage of commercial expansion.

Key numbers

• $1.42 million: Record September-quarter revenue, compared with $470,000 in the corresponding quarter of FY25.
• 191%: FY26 revenue growth to $4.05 million.
• 160-plus: Patients treated across the business, according to the November investor presentation.
• 90 sessions: Potential weekly treatment capacity across the national Empax network.
• $4.745 million: Cash reserves at 30 September 2026.

National expansion is creating a larger commercial opportunity

Emyria's September opening of its first New South Wales Empax clinic at Matilda Nepean Private Hospital extended its specialised treatment network into four Australian states.

The network now encompasses Western Australia, Queensland, Victoria and New South Wales, with 18 treatment beds and capacity for up to 90 dosing sessions each week.

Emyria provides psychiatrist-led treatment programmes for post-traumatic stress disorder (PTSD) and treatment-resistant depression (TRD), using MDMA-assisted and psilocybin-assisted therapies under Australia's Therapeutic Goods Administration (TGA) Authorised Prescriber framework.

The business model combines specialised clinical infrastructure, trained practitioners, treatment protocols and real-world patient data. This provides a platform that could support both direct patient services and partnerships with pharmaceutical companies seeking experienced clinical delivery organisations.

Importantly, the company is already demonstrating that its network can generate meaningful revenue, rather than relying entirely on prospective treatments or future regulatory developments.

Veterans' healthcare could become an important growth driver

One of the more encouraging developments is Emyria's progress towards accessing the government-funded veterans' healthcare market.

The company received its first DVA treatment approvals after the September quarter, with more than 40 referrals already progressing through screening and applications.

This creates an additional potential source of funded patient demand alongside existing private health insurance arrangements, including Medibank-supported treatment pathways.

The immediate priority is converting eligible referrals into approved patients and completed treatment programmes.

If successful, the DVA pathway could improve patient access, increase utilisation across existing clinics and provide greater visibility over future treatment volumes.

US recognition strengthens Emyria's partnership ambitions

Emyria also achieved an important international milestone through its participation in the US Food and Drug Administration's September public hearing examining psychedelic medicines.

Executive Chair Greg Hutchinson was selected to present the company's experience operating within Australia's regulated treatment framework.

The company subsequently appointed former US Secretary of Veterans Affairs Dr David Shulkin as a strategic adviser to support opportunities across American healthcare, veterans' services and research.

Emyria is also in late-stage discussions with an international pharmaceutical sponsor that could become the second participant in its Empax Global Partnership Program.

Although this agreement remains unfinalised, the opportunity is significant because pharmaceutical partnerships could allow Emyria to generate revenue from its existing clinical infrastructure without relying exclusively on direct patient treatment.

Revenue growth is encouraging, but cash generation remains the next test

Financial performance is moving in the right direction.

FY26 revenue reached $4.05 million, representing 191% growth from approximately $1.39 million in FY25. September-quarter revenue then climbed to $1.42 million, more than tripling the corresponding prior-year result.

Cash receipts reached approximately $1.6 million during the September quarter, with another $725,000 in earned revenue awaiting collection.

However, net operating cash outflows totalled approximately $2.28 million, reflecting investment in clinical personnel, national expansion, operational readiness and medication reserves.

Cash reserves stood at approximately $4.745 million at quarter-end.

While this provides funding to continue executing its growth strategy, improving cash conversion will become increasingly important. The opportunity is to increase treatment volumes and clinic utilisation without allowing operating expenditure to grow at the same pace.

The company has also highlighted indicative treatment economics of approximately $22,000 for a typical TRD programme and $33,000 for a PTSD programme. These figures represent potential treatment revenue rather than net profit, but demonstrate the commercial value of successfully delivering funded treatment courses.

What could drive the next stage of growth?

Three developments deserve particular attention during FY27.

First, commencement and expansion of DVA-funded treatments could provide evidence that the veterans' healthcare opportunity is translating into commercial activity.

Second, additional Authorised Prescriber availability and therapist recruitment should help unlock existing clinic capacity, particularly in Perth and Brisbane.

Third, finalising another international pharmaceutical partnership could establish a complementary revenue stream and strengthen the commercial value of Emyria's clinical delivery capabilities.

Insight: Emyria's expanding network could become its greatest commercial advantage

What stands out to us is that Emyria is building more than a specialist treatment business. Its national infrastructure, clinical workforce and accumulated real-world treatment experience could establish a valuable platform for both patient services and pharmaceutical partnerships. Revenue growth of 191% in FY26, followed by record quarterly revenue of $1.42 million, provides encouraging evidence of commercial traction. With 90 weekly treatment sessions available, the next opportunity is to increase utilisation while improving cash generation. DVA treatment volumes will be an important measure of progress.

The verdict: A growing healthcare platform with meaningful commercial potential

Emyria enters the next stage of its development with several encouraging foundations: an established national clinic network, rapidly expanding revenue, growing access to funded patients and increasing international recognition.

The combination of direct clinical services and potential pharmaceutical partnerships gives the business multiple avenues for growth, while its specialised treatment expertise provides an opportunity to establish a differentiated position in an emerging healthcare market.

Funding requirements and execution remain important considerations, particularly while operating cash flow is negative. However, the company now has a more substantial commercial platform from which to pursue its ambitions.

We believe Emyria's progress deserves attention as FY27 unfolds. The key will be demonstrating that expanding patient access and treatment capacity can translate into higher recurring revenue, stronger clinic economics and progressively lower cash consumption.